Sanofi's Venglustat Earns Breakthrough Therapy Designation for Gaucher Disease Type 3

Sanofi has announced that its investigational drug, venglustat, has received the Breakthrough Therapy designation from the US FDA for treating neurological symptoms in patients with type 3 Gaucher disease. This designation, aimed at expediting the development of drugs for serious conditions, is based on results from the LEAP2MONO phase 3 study. The study showed venglustat's significant efficacy in improving neurological symptoms compared to standard enzyme replacement therapy (ERT).

Gaucher disease is a rare lysosomal storage disorder with three types, with GD3 marked by neurological and systemic symptoms. Currently, no approved treatments address the neurological effects. Venglustat targets this by inhibiting abnormal glycosphingolipid accumulation in the central nervous system. Sanofi will continue global regulatory filings for venglustat in 2026.